Journey Medical Corporation - Common Stock (DERM) is currently showing a neutral headline tone with a mixed / range backdrop. The latest news flow is being framed here as context rather than prediction, so beginners can quickly see whether headlines are helping, hurting, or complicating the chart story. Earnings tone is currently no clear earnings read.
HEADLINE TAKE: The current headline mix looks balanced, so the overall news tone reads neutral right now.
Change stock
Search another ticker to view its latest news page.
Full chart, indicators and drawing tools on TradingView. Move to Platforms when you are ready to act.
MyStockHarbor.com
NEWS SCORE
50/100
Neutral
Bearish
Neutral
Bullish
Earnings Tone
55
Neutral based on actual EPS/revenue
Confidence
Low
Headline depth
Last Price
$7.27
Trend Context
Mixed / range
Latest briefing
What's happening with DERM
globenewswire.com19 May 2026
Journey Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in a fireside chat at A.G.P.'s Annual Virtual Healthcare Conference, taking place on…
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
seekingalpha.com13 May 2026
Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
prnewswire.com7 May 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Journey Medical Corporation - DERM
NEW YORK, May 7, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Journey Medical Corporation ("Journey" or the "Company") (NASDAQ: DERM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Article excerpt provided by the FMP news feed. AI is used only for the optional "Why this matters" read.Read full article ↗
Older updates drop into a lighter feed
globenewswire.com
6 May 2026
Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
